Cyanvac
Chemicals & Related Products · Georgia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
111 Riverbend Rd, Athens, Georgia, 30602...Phone Number
(814) 777-4219Website
www.cyanvacllc.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Cyanvac
CyanVac LLC is focused on addressing global infectious diseases through the development of intranasal vaccines utilizing a proprietary parainfluenza virus 5 (PIV5)-based system. Their vaccines aim to block the transmission of viral infections and are designed to be easy to administer, transport, and manufacture. The company targets a worldwide market for vaccine delivery. CyanVac's mission emphasizes the importance of accessible and effective vaccination solutions.Explore more
Cyanvac Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cyanvac your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Cyanvac, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Cyanvac launches new products
Check out if Cyanvac is spiking on competitors!
Funding: Get notified immidiatlly once Cyanvac has new funding data
Check if Cyanvac has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Cyanvac
Website visits: Recent activity has been detected on your website
Click to see if Cyanvac had a recent Job posting/layoffs
Earning: See what the market has to say on Cyanvac recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Cyanvac
Find more new buyers
Compare Similar Companies to Cyanvac
Compare insights from companies similar to Cyanvac, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cyanvac is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cyanvac is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cyanvac.
Cyanvac Tech Stack
A closer look at the technologies used by Cyanvac
Cyanvac News & Media
Blue Lake and CyanVac Report Positive Phase 2a Data for Intranasal COVID-19 Vaccine Candidate
ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, and its affiliate CyanVac LLC, today reported data from a 227-participant Phase 2a clinical trial demonstrating the safety, tolerability, immunogenicity, and efficacy of CVXGA, the company’s intranasal vaccine candidatBlue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress
ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, and its affiliate CyanVac LLC, today announced the presentation of positive interim pediatric clinical data on BLB201, Blue Lake’s vaccine candidate against respiratory syncytial virus (RSV), at the 2024 ISV Annual ConCyanVac Receives BARDA-Funded Project NextGen Award to Evaluate its Intranasal COVID-19 Vaccine Candidate in a Phase 2b Study
ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--CyanVac LLC, a clinical-stage biotechnology company developing intranasal vaccines using a transformational parainfluenza virus 5 (PIV5)-based vector, announced today that it received federal Project NextGen funding to support a comparative Phase 2b study of CVXGA, the company’s PIV5-based vaccine candidate designed to protect against COVID-19. Project NextGen is an initiative of the U.S. Department of Health and Human Services (HHS) to advance nPreclinical Data on PIV5-based Intranasal Vaccine Against Lyme Disease Demonstrates Durable Immune Response
ATHENS, Ga. & MEMPHIS, Tenn.--(BUSINESS WIRE)--CyanVac LLC, a clinical-stage intranasal vaccine company developing PIV5-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, and Immuno Technologies, Inc., a research and development company working on vaccines and diagnostics for Lyme disease, today announced the publication in NPJ Vaccines of preclinical data showing that mice inoculated with a PIV5-based intranasal vaccine against
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cyanvac
Sign Up For FreeTo access detailed company insights
CyanVac LLC is focused on addressing global infectious diseases through the development of intranasal vaccines utilizing a proprietary parainfluenza virus 5 (PIV5)-based system. Their vaccines aim to block the transmission of viral infections and are designed to be easy to administer, transport, and manufacture. The company targets a worldwide mark... Read More
